ClinicalTrials.gg
Active, not recruitingNCT06964724NITROUpdated Nov 18, 2026

NeVa Retrospective Comparative SR Study

An observational study in Stroke Acute, sponsored by Vesalio. Active, not recruiting at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Vesalio · Observational

How we know

Updated Nov 18, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
800
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Stroke with a site in Argentina — 9 open to participants now, 12 under way, 3 of them phase 3. Stroke · Argentina.

Planned enrollment
5th of 13
800 · median 535
Started
2025
with 3 others
Observational
13 of 50
2 open now
Primary completion
2027-02
later than 2 of 11 live
Registered
45th of 50
by date

Among the 50 studies in Stroke with a site in Argentina, this one is the 5th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2025, is one of 13 observational ones, reaches primary completion later than 2 of the 11 other live ones, and was the 45th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

9 of the 50 studies in Stroke with a site in Argentina are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Stroke with a site in Argentina, or all of them as a file.
02

Study summary

To compare safety and effectiveness of NeVa Stent Retriever (SR) to Control SR in the treatment of stroke caused by large vessel occlusion. The main questions it aims to answer are:

How do recanalization rates for NeVa SR compare with those of the Control SR? How does NeVa SR safety compare with Control SR safety?

Read the detailed description

NITRO is a multicenter, retrospective, comparative, non-inferiority, cohort study designed to compare NeVa SR with Control SR for safety and effectiveness when removing thrombus in subjects presenting with acute ischemic stroke (AIS) due to large vessel occlusion (LVO). The objective of the NeVa International, Multi-center, Retrospective Comparative stent retriever (SR) study (NITRO) study is to compare safety and effectiveness of the NeVa SR to commonly used SR with CE-mark, and US FDA clearance, to restore blood flow in patients experiencing acute ischemic stroke due to large intracranial vessel occlusion. NITRO aims to collect data describing real-world clinical practices when using SRs according to their indicated use within the indicated population. As such, the eligibility criteria define patients who are diagnosed with AIS and are indicated for endovascular MT aligning to the target population for the proposed device. The present study will include data from subjects treated with either NeVa SR or one of the Control SR. Control SR will include any SR commonly used in thrombectomy trials as first-line strategies and which represent CE-mark, and US FDA cleared stent retrievers.

03

Conditions studied

  • Stroke Acute

Browse trials for

Keywords

  • NeVa
  • Mechanical Thrombectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects suffering from acute ischemic stroke from large vessel occlusion treated with study device.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment during the enrollment period
  • Age ≥18
  • Baseline modified Thrombolysis in Cerebral Infarction (mTICI) score ≤ 1
  • Pre-stroke modified Rankin score (mRS) of 0 or 1
  • Internal Carotid Artery (ICA), Middle Cerebral Artery (first segment M1/ second segment M2), basilar artery or vertebral artery occlusion
  • National Institutes of Health Stroke Scale (NIHSS) score ≥ 8 and ≤ 25
  • Thrombectomy procedure initiated within 8h of Time Last Known Well (TLKW)
  • Intravenous Tissue Plasminogen Activator (IV-tPA) failed, given within 3h of TLKW, or ineligibility for thrombolytic drug

Exclusion criteria

Exclusion Criteria:

  • contact aspiration alone or non-study device as first-line device
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients experiencing acute ischemic stroke due to large vessel occlusion

    According to Guidelines AIS patients due to LVO should receive mechanical thrombectomy (with a stent retriever) under certain conditions.

    Procedure: Mechanical thrombectomy

Interventions

  • ProcedureMechanical thrombectomy

    Mechanical thrombectomy with stent retriever

06

What researchers measure

Primary outcomes

  1. Reperfusion Effectiveness

    Number of patients with a Modified Thrombolysis in cerebral infarction (mTICI) ≥2B and mTICI≥2C recanalization after 1st pass and at end of procedure

    Time frame: Procedural

Secondary outcomes

  1. Procedural symptomatic bleeding events

    Number of patients experiencing symptomatic intracranial hemorrhage (sICH)

    Time frame: Within 24 hours post intervention

  2. Procedure Safety

    Number of patients experiencing procedure related serious Adverse Events (PRSAE)

    Time frame: Within 24 hours post intervention

  3. Device relationship to serious adverse events

    Number of patients experiencing a serious adverse device effect (SADE)

    Time frame: Within 24 hours post intervention

Other outcomes

  1. Functional Independence at 90 days

    Number of patients with a Modified Rankin Scale (mRS) 0-2

    Time frame: At 90 Days

  2. 90-day Mortality

    Number of patients that died at 90-days from any cause

    Time frame: Within 90 days post intervention

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: Undecided — At this stage not yet discussed how or at which URL the Protocol defined Endpoints will be made available.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 19 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Jun 2026 → Feb 2027 and completion Sep 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2025
First posted
May 9, 2025
StartActual
Jun 15, 2025
Primary completionEst.
Feb 1, 2027was Jun 2026
CompletionEst.
Feb 1, 2027was Sep 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Hospital Espanol de Mendoza · Mendoza, Argentina
Show 1 removed
  • Hospital Espanol de Mendoza · Mendoza, Argentina
Nov 18, 2026
Primary completion
Jun 1, 2026→Feb 1, 2027
Nov 18, 2026
Study completion
Sep 1, 2026→Feb 1, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    1 site added, 1 site removed
    Show site
    • Hospital Espanol de Mendoza · Mendoza, Argentina
    Show 1 removed
    • Hospital Espanol de Mendoza · Mendoza, Argentina
    Primary completion Jun 1, 2026→Feb 1, 2027
    Study completion Sep 1, 2026→Feb 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06964724
Lead sponsor
Vesalio
Responsible party
Sponsor
First posted
May 9, 2025
Start date
Jun 15, 2025
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Antoine Cuijpers, MSc
study director · Vesalio

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion